U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Hodgkin Lymphoma

MedGen UID:
208949
•Concept ID:
C0855082
•
Neoplastic Process
Synonyms: Refractory Hodgkin lymphoma; Refractory Hodgkin's disease; Refractory Hodgkin's Disease; Refractory Hodgkin's Lymphoma; Refractory Hodgkin's lymphoma
SNOMED CT: Refractory Hodgkin's disease (461311000124107); Refractory Hodgkin's lymphoma (461311000124107); Refractory Hodgkin lymphoma (461311000124107)

Definition

Hodgkin lymphoma resistant to treatment [from NCI]

Professional guidelines

PubMed

Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation.
Blum KA
Cancer J 2018 Sep/Oct;24(5):244-248. doi: 10.1097/PPO.0000000000000330. PMID: 30247260
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT
Int J Radiat Oncol Biol Phys 2018 Apr 1;100(5):1100-1118. Epub 2018 Jan 9 doi: 10.1016/j.ijrobp.2018.01.011. PMID: 29722655
Treatment of relapsed and refractory Hodgkin Lymphoma.
von Tresckow B, Moskowitz CH
Semin Hematol 2016 Jul;53(3):180-5. Epub 2016 May 12 doi: 10.1053/j.seminhematol.2016.05.010. PMID: 27496309Free PMC Article

Recent clinical studies

Etiology

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF
Blood 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. PMID: 33827139
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH
Blood 2019 Oct 3;134(14):1144-1153. Epub 2019 Aug 13 doi: 10.1182/blood.2019000324. PMID: 31409671Free PMC Article
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT
Int J Radiat Oncol Biol Phys 2018 Apr 1;100(5):1100-1118. Epub 2018 Jan 9 doi: 10.1016/j.ijrobp.2018.01.011. PMID: 29722655
Transplant strategies in relapsed/refractory Hodgkin lymphoma.
Shah GL, Moskowitz CH
Blood 2018 Apr 12;131(15):1689-1697. Epub 2018 Mar 2 doi: 10.1182/blood-2017-09-772673. PMID: 29500170Free PMC Article
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291

Diagnosis

Checkpoint inhibition in lymphoma.
Shah GL, Moskowitz CH
Clin Adv Hematol Oncol 2018 Jan;16(1):45-55. PMID: 29741505
Treatment of relapsed and refractory Hodgkin Lymphoma.
von Tresckow B, Moskowitz CH
Semin Hematol 2016 Jul;53(3):180-5. Epub 2016 May 12 doi: 10.1053/j.seminhematol.2016.05.010. PMID: 27496309Free PMC Article
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291
Brentuximab vedotin.
van de Donk NW, Dhimolea E
MAbs 2012 Jul-Aug;4(4):458-65. Epub 2012 Jul 1 doi: 10.4161/mabs.20230. PMID: 22684302Free PMC Article
Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.
David KA, Mauro L, Evens AM
Curr Treat Options Oncol 2007 Oct;8(5):352-74. doi: 10.1007/s11864-007-0046-9. PMID: 18214690

Therapy

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF
Blood 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. PMID: 33827139
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B
J Clin Oncol 2020 Nov 10;38(32):3794-3804. Epub 2020 Jul 23 doi: 10.1200/JCO.20.01342. PMID: 32701411Free PMC Article
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH
Blood 2019 Oct 3;134(14):1144-1153. Epub 2019 Aug 13 doi: 10.1182/blood.2019000324. PMID: 31409671Free PMC Article
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT
Int J Radiat Oncol Biol Phys 2018 Apr 1;100(5):1100-1118. Epub 2018 Jan 9 doi: 10.1016/j.ijrobp.2018.01.011. PMID: 29722655
Transplant strategies in relapsed/refractory Hodgkin lymphoma.
Shah GL, Moskowitz CH
Blood 2018 Apr 12;131(15):1689-1697. Epub 2018 Mar 2 doi: 10.1182/blood-2017-09-772673. PMID: 29500170Free PMC Article

Prognosis

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF
Blood 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. PMID: 33827139
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH
Blood 2019 Oct 3;134(14):1144-1153. Epub 2019 Aug 13 doi: 10.1182/blood.2019000324. PMID: 31409671Free PMC Article
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R
Blood 2018 Jul 5;132(1):40-48. Epub 2018 Apr 27 doi: 10.1182/blood-2017-11-815183. PMID: 29703778Free PMC Article
Treatment of relapsed and refractory Hodgkin Lymphoma.
von Tresckow B, Moskowitz CH
Semin Hematol 2016 Jul;53(3):180-5. Epub 2016 May 12 doi: 10.1053/j.seminhematol.2016.05.010. PMID: 27496309Free PMC Article
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291

Clinical prediction guides

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B
J Clin Oncol 2020 Nov 10;38(32):3794-3804. Epub 2020 Jul 23 doi: 10.1200/JCO.20.01342. PMID: 32701411Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R
Blood 2018 Jul 5;132(1):40-48. Epub 2018 Apr 27 doi: 10.1182/blood-2017-11-815183. PMID: 29703778Free PMC Article
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH
Blood 2018 Mar 15;131(11):1183-1194. Epub 2017 Dec 11 doi: 10.1182/blood-2017-10-811224. PMID: 29229594Free PMC Article
Modern treatment of Hodgkin lymphoma.
Bartlett NL
Curr Opin Hematol 2008 Jul;15(4):408-14. doi: 10.1097/MOH.0b013e328302c9d8. PMID: 18536581

Recent systematic reviews

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.
Zinzani PL, Sasse S, Radford J, Gautam A, Bonthapally V
Crit Rev Oncol Hematol 2016 Aug;104:65-70. Epub 2016 May 21 doi: 10.1016/j.critrevonc.2016.04.019. PMID: 27279289
Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
Dada R, Zekri J, Al Saadi R
Expert Opin Biol Ther 2016 Jun;16(6):739-45. Epub 2016 May 3 doi: 10.1080/14712598.2016.1180362. PMID: 27096887
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P, Bruno B
Expert Opin Biol Ther 2016;16(3):347-64. Epub 2016 Feb 6 doi: 10.1517/14712598.2015.1130821. PMID: 26652934
Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
Zinzani PL, Sasse S, Radford J, Shonukan O, Bonthapally V
Crit Rev Oncol Hematol 2015 Sep;95(3):359-69. Epub 2015 Apr 27 doi: 10.1016/j.critrevonc.2015.03.011. PMID: 25964164
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D
Curr Med Res Opin 2015 May;31(5):993-1001. Epub 2015 Apr 9 doi: 10.1185/03007995.2015.1030378. PMID: 25772232

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...